ArticleFrontiers in oncology2025
Correlation analysis between plasma circulating tumour deoxyribonucleic acid variations and survival in patients with hepatocellular carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MUC16 promotes endometrial cancer progression and modulates sensitivity to lapatinib through the ESR1/PI3K/AKT axis.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to analyse the variation of circulating tumour DNA (ctDNA) in patients with hepatocellular carcinoma (HCC). Methods: Newly diagnosed patients with HCC admitted between March 2022 and October 2023 were prospectively enrolled. Plasma ctDNA testing was performed before treatment, and clinical information, treatment regimens and survival data were collected. Results: A total of 166 patients with HCC were enrolled, including 127 men and 39 women, with a mean age of 58.1±10.0 years. Of these, 137 patients were infected with hepatitis B virus, and 129 had underlying cirrhosis. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, 74, 20, 52 and 20 patients were classified as stages A, B, C and D, respectively. Tumour mutation burden (TMB) ranged from 0 to 35.48 mutations per Mb; it increased with higher BCLC stages but decreased in stage D. The top five mutated genes were Conclusion: Circulating tumour DNA testing demonstrated that TMB is closely associated with OS in patients with HCC. Patients with HCC with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.